Zobrazeno 1 - 10
of 951
pro vyhledávání: '"Epoetin beta"'
Autor:
Hiroaki Io, Masahiro Muto, Yu Sasaki, Masanori Ishizaka, Toshiki Kano, Haruna Fukuzaki, Takuya Maeda, Yuki Shimizu, Junichiro Nakata, Yusuke Suzuki
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Anemia in patients with chronic kidney disease (p-CKDs) may initiate or exacerbate left ventricular hypertrophy (LVH). This study aimed to determine whether treatment using long-acting erythropoietin-stimulating agents (L-ESAs) is
Externí odkaz:
https://doaj.org/article/81ffa2ba55f0490ebef402e8ba4631e2
Publikováno v:
Heliyon, Vol 9, Iss 2, Pp e13747- (2023)
Background: Chronic kidney disease (CKD) is a global disease, and the number of people affected is increasing due to driving factors such as diabetes, obesity, and hypertension, as well as increased life expectancy. Many patients with CKD suffer anem
Externí odkaz:
https://doaj.org/article/436a992741ab4b44837756e23d5e5adf
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 174-182 (2021)
Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign. At the same time,
Externí odkaz:
https://doaj.org/article/f55e77dd167e42f0a0080d404289f5dd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Takahide Iwasaki, Akira Fujimori, Takeshi Nakanishi, Shioko Okada, Nobuto Hanawa, Yukiko Hasuike, Takahiro Kuragano
Publikováno v:
BMC Nephrology, Vol 22, Iss 1, Pp 1-9 (2021)
Abstract Background Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a factor
Externí odkaz:
https://doaj.org/article/c40107665c2f43a59a5fc3f11d20d8d5
Autor:
Yasuki Shingu, Tomohiro Nakata, Shinji Sawai, Hisaya Tanaka, Osamu Asai, Keiichi Tamagaki, Kimihiko Nakatani
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-5 (2020)
Abstract Background Erythropoietin-stimulating agents (ESAs) are used to treat anemia in patients with chronic kidney disease, enabling maintenance of stable hemoglobin levels and eliminating the need for multiple transfusions. Epoetin-beta pegol (C.
Externí odkaz:
https://doaj.org/article/996ed54163224dd8bf94e2bc405bb5eb
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 146, Iss , Pp 112502- (2022)
Antibodies that bind polyethylene glycol (PEG) can be induced by pegylated biomolecules and also exist in a significant fraction of healthy individuals who have never received pegylated medicines. The binding affinity of antibodies against PEG (anti-
Externí odkaz:
https://doaj.org/article/370a0caeb29b4be5863b7f130df53668
Publikováno v:
Pharmaceuticals, Vol 16, Iss 2, p 164 (2023)
The present work investigates the effects of chitosan-hyaluronic acid-epoetin beta (CS/HA-EPOβ) nanoparticles after topical ocular administration in a rat glaucoma model. Wistar Hannover rats (n = 24) were submitted to a complete ophthalmological ex
Externí odkaz:
https://doaj.org/article/1f19d5ac502349b7b26e71274b08f0cd
Autor:
Hidehiro Tabata, Hiroyuki Kanno, Ayako Murayama, Tadashi Ishii, Ryosuke Harada, Yukio Udagawa
Publikováno v:
Renal Replacement Therapy, Vol 5, Iss 1, Pp 1-12 (2019)
Abstract Background This observational study investigated the safety and effectiveness of continuous erythropoietin receptor activator in patients with renal anemia in Japan. Methods Patients were enrolled between August 2011 and November 2015 and fo
Externí odkaz:
https://doaj.org/article/92db8728fd7c448aad3504999996fab7
Autor:
Hideki, Fujii, Takayuki, Hamano, Ken, Tsuchiya, Takahiro, Kuragano, Nobuhiko, Joki, Kazuhiko, Tsuruya, Hirokazu, Honda, Yukari, Uemura, Kosaku, Nitta
Publikováno v:
International Journal of Cardiology. 375:110-118
Responsiveness to erythropoiesis-stimulating agents (ESAs) has been reported to be associated with increased cardiovascular disease (CVD) and mortality in patients undergoing hemodialysis (HD). However, the association between hyporesponsiveness to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25751bd675a669777096bef86322600
https://hdl.handle.net/20.500.14094/0100481690
https://hdl.handle.net/20.500.14094/0100481690